142 related articles for article (PubMed ID: 28837921)
1. Discovery of BAZ2A bromodomain ligands.
Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
[TBL] [Abstract][Full Text] [Related]
2. Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains.
Dalle Vedove A; Spiliotopoulos D; D'Agostino VG; Marchand JR; Unzue A; Nevado C; Lolli G; Caflisch A
ChemMedChem; 2018 Jul; 13(14):1479-1487. PubMed ID: 29770599
[TBL] [Abstract][Full Text] [Related]
3. Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
Dalle Vedove A; Cazzanelli G; Batiste L; Marchand JR; Spiliotopoulos D; Corsi J; D'Agostino VG; Caflisch A; Lolli G
ACS Med Chem Lett; 2022 Sep; 13(9):1434-1443. PubMed ID: 36105334
[TBL] [Abstract][Full Text] [Related]
4. Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining.
Dalle Vedove A; Cazzanelli G; Corsi J; Sedykh M; D'Agostino VG; Caflisch A; Lolli G
ACS Bio Med Chem Au; 2021 Dec; 1(1):5-10. PubMed ID: 36147311
[TBL] [Abstract][Full Text] [Related]
5. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
[TBL] [Abstract][Full Text] [Related]
6. High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient in Silico Screening for X-Ray Crystallography.
Lolli G; Caflisch A
ACS Chem Biol; 2016 Mar; 11(3):800-7. PubMed ID: 26942307
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of bromodomain ligands targeting BAZ2A.
Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
[TBL] [Abstract][Full Text] [Related]
8. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
9. Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation.
Marchand JR; Lolli G; Caflisch A
J Med Chem; 2016 Nov; 59(21):9919-9927. PubMed ID: 27731638
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
[TBL] [Abstract][Full Text] [Related]
11. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based in silico screening of bromodomain ligands.
Spiliotopoulos D; Caflisch A
Drug Discov Today Technol; 2016 Mar; 19():81-90. PubMed ID: 27769362
[TBL] [Abstract][Full Text] [Related]
13. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
14. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
Drouin L; McGrath S; Vidler LR; Chaikuad A; Monteiro O; Tallant C; Philpott M; Rogers C; Fedorov O; Liu M; Akhtar W; Hayes A; Raynaud F; Müller S; Knapp S; Hoelder S
J Med Chem; 2015 Mar; 58(5):2553-9. PubMed ID: 25719566
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking.
Marchand JR; Dalle Vedove A; Lolli G; Caflisch A
J Chem Inf Model; 2017 Oct; 57(10):2584-2597. PubMed ID: 28862840
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of selective BRPF1 bromodomain inhibitors.
Zhu J; Zhou C; Caflisch A
Eur J Med Chem; 2018 Jul; 155():337-352. PubMed ID: 29902720
[TBL] [Abstract][Full Text] [Related]
17. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
[TBL] [Abstract][Full Text] [Related]
18. Twenty Crystal Structures of Bromodomain and PHD Finger Containing Protein 1 (BRPF1)/Ligand Complexes Reveal Conserved Binding Motifs and Rare Interactions.
Zhu J; Caflisch A
J Med Chem; 2016 Jun; 59(11):5555-61. PubMed ID: 27167503
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of the TAM domain of BAZ2A in binding to DNA or RNA independent of methylation status.
Chen S; Zhou M; Dong A; Loppnau P; Wang M; Min J; Liu K
J Biol Chem; 2021 Dec; 297(6):101351. PubMed ID: 34715126
[TBL] [Abstract][Full Text] [Related]
20. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation.
Yang Z; Zhou Y; Zhong L
Bioorg Med Chem Lett; 2021 Feb; 33():127745. PubMed ID: 33333161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
